Skip to main content

Table 1 Patient characteristicsa

From: Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series

  Site of primary (P) and metastases (M) Prior treatment Morphology Multifocal (MF)
Tumour size
Mitotic index (MI)
KIT/PDGFRA mutation status Other clinical features of particular relevance
Patient A P – Stomach
M – Liver
R2 surgery, imatinib Epithelioid MF- Yes
11.0 cm
MI >10/50 HPF
Both WT GI bleeding, palpable tumour
Patient B P – Stomach
M– Liver
– IP cavity
R2 surgery then imatinib after recurrence Mixed MF –no
3.0 cm
MI 6/50 HPF
Both WT GI bleeding
Patient C P – Stomach
M – Liver
– IP Cavity
R2 surgery, imatinib Epithellioid MF – yes
6.0 cm
MI NA
Both WT GI bleeding
Patient D P – Stomach
– IP cavity
R2 surgery, imatinib Mixed MF – yes
11.0 cm
MI 05/50 HPF
Both WT GI bleeding
Patient E P – Stomach
M – Omentum
Surgery, imatinib at first progression Mixed MF – Yes
7.0 cm
10/50 HPF
Both WT GI bleeding from tumour
Patient F P – Stomach
M – None
Surgery at diagnosis and recurrence Epithelioid MF – No
4.5 cm
MI 50//10 HPF
Both WT Pain, nausea, vomiting, GI bleeding from tumour
Patient G P – Stomach
M – None
Surgery Mixed MF – No
10.0 cm
MI 17/50 HPF
Both WT Abdominal pain
Patient H P – Stomach
M – Liver
– IP cavity
Imatinib Spindle MF-yes
NA
MI 1/20 HP
Both WT Marked anaemia
Patient I P – Stomach
M – Liver
Surgery, imatinib Spindle MF-no
3 cm
MI 20/50 HPF
Both WT Melaena and anaemia
  1. aTo maintain patient anonymity individual data relating to age, gender, height, bodyweight, date of diagnosis, age at diagnosis and start of sunitinib therapy are summarised in the results section
  2. HPF = high powered field; GI = gastrointestinal; IP = intraperitoneal; NA = not available; R2 = macroscopic residual tumour on resection; WT = wild type